{"title": "Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination - Full Text View - ClinicalTrials.gov", "author": null, "url": "https://clinicaltrials.gov/ct2/show/NCT04706390", "hostname": "clinicaltrials.gov", "description": "Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination - Full Text View.", "sitename": "ClinicalTrials.gov", "date": "2021-01-12", "cleaned_text": "Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination (COVID19vac-1) | The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. | |ClinicalTrials.gov Identifier: NCT04706390| | | Recruitment Status : Recruiting First Posted : January 12, 2021 Last Update Posted : August 9, 2021 - Study Details [Tabular View](/ct2/show/record/NCT04706390) [No or disease||Intervention/treatment| |Covid19||Biological: covid-19 vaccine| The primary aim of this study is - To compare immune responses after natural SARS-CoV-2 infection and COVID-19 vaccination The secondary aims are - To compare the duration and breadth of antibody responses between natural infection and vaccination. - To investigate the duration and breadth of B and T cellular responses between natural infection and vaccination. - To evaluate the short and long term complications after natural infection and vaccination. - To find out if previous infection skews the immune response after vaccination. - To study reinfection after natural infection and vaccination. to Natural COVID-19 Infection and Vaccination| |Actual Study Start Date :||January 12, 2021| |Estimated Primary Date :||January care workers | 500-1000 health care workers prioritized for early vaccination | Biological: covid-19 vaccine | vaccination | prioritized patient populations | 2000 individuals in patient populations prioritized for vaccinations | Biological: covid-19 vaccine | vaccination - immune responses [ Time Frame: 2 months to 3 years ]spike antibody response to SARS-CoV-2 - Duration and breadth of B- cell responses [ Time Frame: 2 months to 3 years ]compare serological and memory B cells after vaccination to natural infection - Duration and breadth of T cell responses [ Time Frame: 2 months to 3 years ]compare T cell responses after vaccination to natural infection Biospecimen Retention: Samples With DNA Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies.](/ct2/about-studies/learn) |Ages Eligible for Study:||20 Years to 100 Years |Sexes Eligible for Study:||All| |Sampling Method:||Non-Probability Sample| Inclusion Criteria: - subjects prioritized by national vaccination program Exclusion Criteria: - Children - unable or unwilling to provide informed consent To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04706390 |Contact: Rebecca J Cox, PhD||+4745242974|| |[nina.langeland@uib.no](mailto:nina.langeland%40uib.no?subject=NCT04706390, COVID-19vacc-1, Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination) |Norway| |University of Bergen||Recruiting| |Bergen, PhD 45242974 |[nina.langeland@uib.no](mailto:nina.langeland%40uib.no?subject=NCT04706390, COVID-19vacc-1, Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination) |Principal Investigator:||Rebecca J Cox, Langeland N; Bergen COVID-19 Research Group. Seroconversion in household members of COVID-19 outpatients. Lancet Infect Dis. 2021 Feb;21(2):168. doi: 10.1016/S1473-3099(20)30466-7. Epub 2020 Jun 15. No Infect Dis. 2020 Sep;20(9):e215.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFnLgCRaK4wA6h9Ei4L3BUgWwNG0it.) [Trieu RJ; Bergen COVID-19 Research Group. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. J Infect Dis. 2021 Feb 24;223(4):589-599. doi: Device Product:||No| | Covid19 | Vaccine SARS-CoV-2 antibody | COVID-19 | Infections Pneumonia, Viral Pneumonia Respiratory Tract Infections Virus Diseases | Coronavirus Infections | Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases "}